UPDATE: Affy Cuts Q2 Revenue Outlook on Lower Sales of GeneChips, Spot Arrayers | GenomeWeb

This story has been updated from a previous version.
 
NEW YORK, June 11 - Affymetrix said Monday it was reducing its second quarter revenue forecast to between $44 million and $50 million, down from a previously expected $56 million, citing lower than expected orders of GeneChips and a drop in the demand for spotted array instrumentation.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.